hVIVOOPORF +27.29%43 FCF Yield % is -29.33 as of Jun. 26, 2026. GuruFocus rates OPORF with a GF Score™ of 43/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, hVIVO ranks worse than 86.51% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, hVIVO's Trailing 12-Month Free Cash Flow is $-21.36 Mil, and Market Cap is $65.70 Mil. Therefore, hVIVO's FCF Yield % for today is -29.33%.
The historical rank and industry rank for hVIVO's FCF Yield % or its related term are showing as below:
OPORF'
s FCF Yield % Range Over the Past 10 Years
Min: -166.52 Med: -0.61 Max: 22.89
Current: -29.33
During the past 13 years, the highest FCF Yield % of hVIVO was 22.89%. The lowest was -166.52%. And the median was -0.61%.
OPORF's FCF Yield % is ranked worse than 86.51% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.41
vs OPORF: -29.33
hVIVO's FCF Margin % for the quarter that ended in Dec. 2025 was -34.29%.
hVIVO FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
hVIVO FCF Yield % Related Terms
hVIVO FCF Yield % Historical Data
* Premium members only.
The historical data trend for hVIVO's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, hVIVO's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's FCF Yield % distribution charts can be found below:
* The bar in red indicates where hVIVO's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO (OPORF) has a FCF Yield % of -29.33 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on hVIVO and its competitors. According to the industry distribution chart, hVIVO ranks #186 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 86.5%.
Is hVIVO's FCF Yield % too high?
hVIVO's current FCF Yield % is -29.33. Based on the distribution chart, hVIVO ranks #186 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, hVIVO has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #186 out of 215 companies for FCF Yield %. This places hVIVO in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on hVIVO and its competitors. hVIVO's current FCF Yield % is -29.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current FCF Yield % is -29.33. hVIVO's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For hVIVO (OPORF), the current FCF Yield % is -29.33 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
FCF Yield %: -29.33
GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score
Get the complete analysis for OPORF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
